Pharma Mar (WBO:PHM) Retained Earnings : €168.4 Mil (As of Dec. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Pharma Mar Retained Earnings?

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Pharma Mar's retained earnings for the quarter that ended in Dec. 2024 was €168.4 Mil.

Pharma Mar's quarterly retained earnings increased from Jun. 2024 (€144.4 Mil) to Sep. 2024 (€148.4 Mil) and increased from Sep. 2024 (€148.4 Mil) to Dec. 2024 (€168.4 Mil).

Pharma Mar's annual retained earnings declined from Dec. 2022 (€156.5 Mil) to Dec. 2023 (€142.2 Mil) but then increased from Dec. 2023 (€142.2 Mil) to Dec. 2024 (€168.4 Mil).

Pharma Mar Retained Earnings Historical Data

The historical data trend for Pharma Mar's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharma Mar Retained Earnings Chart

Pharma Mar Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Retained Earnings

Get a 7-Day Free Trial

41.87

121.29

156.51

142.22

168.38

Pharma Mar Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Retained Earnings	Get a 7-Day Free Trial															142.22	144.09	144.43	148.42	168.38

Pharma Mar Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

Pharma Mar (WBO:PHM) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.

Pharma Mar Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharma Mar SA (WBO:PHM) » Definitions » Retained Earnings

Comparable Companies

Traded in Other Exchanges

PHMMF:USA PHMe:UK 0RC6:UK PHM:Spain PMRA:Germany PMRA:Germany

Address

Avenida de los Reyes, 1, Poligono Industrial La Mina-norte, Colmenar Viejo, Madrid, ESP, 28770

Website

http://www.pharmamar.com

Pharma Mar SA is engaged in the research, development, production, and commercialization of bio-active principles of marine origin for application in oncology. It also produces and markets insecticides and air fresheners for household use, household products, wood treatment and decoration products, paints, and similar products. Its operating business segments are Oncology and RNAi. The company obtains its revenues from two main areas: biopharmaceuticals and consumer chemicals, but the biopharmaceuticals is the main line of business.